Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial


Sävendahl L., Battelino T., Brod M., Rasmussen M. H., Horikawa R., Juul R. V., ...Daha Fazla

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, cilt.105, sa.4, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 105 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1210/clinem/dgz310
  • Dergi Adı: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, Food Science & Technology Abstracts, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: growth hormone, growth hormone deficiency, growth hormone replacement therapy, long-acting growth hormone, somapacitan, treatment burden, GROWTH-HORMONE, REFERENCE INTERVALS, IGF-I, INSULIN, MULTICENTER, POSSESSES, SAFETY, ANALOG
  • Marmara Üniversitesi Adresli: Evet

Özet

Context: Daily growth hormone (GH) injections can be burdensome for patients and carers. Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD).